نمایش پرونده ساده آیتم

dc.contributor.authorAbdolalizadeh, J
dc.contributor.authorNouri, M
dc.contributor.authorZolbanin, JM
dc.contributor.authorBaradaran, B
dc.contributor.authorBarzegari, A
dc.contributor.authorOmidi, Y
dc.date.accessioned2018-08-26T08:52:00Z
dc.date.available2018-08-26T08:52:00Z
dc.date.issued2012
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53595
dc.description.abstractUsing phage display technology (PDT), we have recently isolated single-chain variable fragment (scFv) antibodies (Ab) against some pivotal molecular markers involved in malignancies and systemic inflammation including human tumor necrosis factor-alpha (TNF-?, GI:367465798). Downstream purification and characterization of scFv antibodies is a challenging issue, which may impose substantial impacts on quality of the final product(s). Of various purification methods, affinity chromatography has widely been used in the pharmaceutical grade downstream processing (PGDP) of proteins (e.g., monoclonal antibody (mAb) and scFvs). To pursue an optimized PGDP, in the current study, we have capitalized PDT for upstream selection of anti-TNF-? scFvs and protein A affinity chromatography (PAAC) for downstream extraction and purification of the scFvs from the crude medium secreted and periplasmic fractions of HB2151 cells. The versatility of the PDT selection was validated using SDS-PAGE electrophoresis, western blot, dot blot, ELISA and fluorescence microscopy. SDS-PAGE western blot analyses displayed a 17 kDa scFv with high purity (> 98%), while dot blot and ELISA analyses showed high specificity and binding affinity of the purified scFv antibody fragments toward human TNF-? at nM range. Fluorescence microscopy further confirmed detection of TNF-? in Raji B lymphoblast cells. Finally, based on our findings, we believe that these PDT selected and PAAC processed scFvs may be used as targeting and/or therapy agent for TNF-? mediated diseases. Further, to increase the production yield, downstream purification techniques need to be optimized for the large scale production of scFv antibodies. é 2012 - IOS Press and the authors. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofHuman Antibodies
dc.subjectprotein A
dc.subjectsingle chain fragment variable antibody
dc.subjecttumor necrosis factor alpha
dc.subjectaffinity chromatography
dc.subjectantibody detection
dc.subjectarticle
dc.subjectB lymphoblast
dc.subjectcontrolled study
dc.subjectcytoplasm
dc.subjectdownstream processing
dc.subjectenzyme linked immunosorbent assay
dc.subjectfluorescence microscopy
dc.subjectnonhuman
dc.subjectphage display
dc.subjectpolyacrylamide gel electrophoresis
dc.subjectpriority journal
dc.subjectWestern blotting
dc.subjectAntibodies, Monoclonal
dc.subjectAntibody Specificity
dc.subjectBlotting, Western
dc.subjectCell Line
dc.subjectChromatography, Affinity
dc.subjectElectrophoresis, Polyacrylamide Gel
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectHumans
dc.subjectMicroscopy, Fluorescence
dc.subjectPeptide Library
dc.subjectSingle-Chain Antibodies
dc.subjectTumor Necrosis Factor-alpha
dc.titleDownstream characterization of anti-TNF-? single chain variable fragment antibodies
dc.typeArticle
dc.citation.volume21
dc.citation.issue1-2
dc.citation.spage41
dc.citation.epage48
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.3233/HAB-2012-0260


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم